Novartis International AG (NYSE: NVS) operates within the global pharmaceutical and biotechnology industry, an environment characterized by rapid scientific innovation, stringent regulatory oversight, and intense pricing pressures1. Following a multi-year strategic transformation that culminated in the October 2023 spin-off of its Sandoz generics and biosimilars division, Novartis has repositioned itself as a pure-play innovative medicines conglomerate2. The overarching corporate strategy is defined by a concentrated focus on four core therapeutic areas: cardiovascular-renal-metabolic (CRM), immunology, neuroscience, and oncology3. To support these therapeutic pillars, the company is prioritizing advanced technology platforms, specifically chemistry, biotherapeutics, gene and cell therapy, radioligand therapy (RLT), and xRNA.

The industry i ...